

## Ethiopia HPV Demonstration Vaccine Support

**This Decision Letter sets out the Terms of a Programme.**

<b>1. Country:</b> Ethiopia																
<b>2. Vaccines Grant Number:</b> 1516-ETH-19b-X <b>Cash Support Grant Number:</b> 1516-ETH-24a-Y																
<b>3. Date of Decision Letter:</b> 2 July 2015																
<b>4. Date of the Partnership Framework Agreement:</b> 23 July 2013																
<b>5. Programme Title:</b> HPV Demonstration Programme																
<b>6. Vaccine type:</b> HPV																
<b>7. Preferred product presentation and formulation of vaccine:</b> HPV Quadrivalent, 1 dose(s) per vial, LIQUID																
<b>8. Programme Duration<sup>1</sup>:</b> 2015 - 2016																
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement):																
<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 35%;"></th> <th style="width: 15%;">2015</th> <th style="width: 15%;">2016</th> <th style="width: 35%;">Total<sup>2</sup></th> </tr> </thead> <tbody> <tr> <td>HPV vaccines</td> <td style="text-align: right;">US\$79,500</td> <td style="text-align: right;">US\$72,000</td> <td style="text-align: right;">US\$151,500</td> </tr> <tr> <td>Cash</td> <td style="text-align: right;">US\$170,000</td> <td style="text-align: right;">US\$25,000</td> <td style="text-align: right;">US\$195,000</td> </tr> <tr> <td><b>Total Programme Budget</b></td> <td style="text-align: right;"><b>US\$249,500</b></td> <td style="text-align: right;"><b>US\$97,000</b></td> <td style="text-align: right;"><b>US\$346,500</b></td> </tr> </tbody> </table>		2015	2016	Total <sup>2</sup>	HPV vaccines	US\$79,500	US\$72,000	US\$151,500	Cash	US\$170,000	US\$25,000	US\$195,000	<b>Total Programme Budget</b>	<b>US\$249,500</b>	<b>US\$97,000</b>	<b>US\$346,500</b>
	2015	2016	Total <sup>2</sup>													
HPV vaccines	US\$79,500	US\$72,000	US\$151,500													
Cash	US\$170,000	US\$25,000	US\$195,000													
<b>Total Programme Budget</b>	<b>US\$249,500</b>	<b>US\$97,000</b>	<b>US\$346,500</b>													
<b>10. Vaccine Introduction Grant:</b> Not applicable																

<sup>1</sup> This is the entire duration of the programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the programme.

**11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):<sup>3</sup>**

*Vaccines:*

Type of supplies to be purchased with Gavi funds in each year	2015	2016
Number of HPV vaccines doses	16,700	15,200
Number of AD syringes	17,600	15,900
Number of safety boxes	200	175
Annual Amounts (US\$)	US\$79,500	US\$72,000

*Cash support:*

Cash Support by year	2015
Annual Amounts (US\$)	US\$170,000

**12. Procurement agency:** UNICEF

**13. Self-procurement:** Not applicable

**14. Co-financing obligations:** Not applicable

**15. Operational support for campaigns:** Not applicable

---

<sup>3</sup> This is the amount that Gavi has approved.

**16. Documents to be delivered for future disbursements:** The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts. Further details can be found in the HPV Application Guidelines.

Reports, documents and other deliverables	Due dates
<ol style="list-style-type: none"> <li>1. A copy of the approval by the local ethics committee, <i>if a country determined that review and approval was required.</i></li> <li>2. Three evaluation reports of the HPV vaccination demonstration programme:               <ol style="list-style-type: none"> <li>a. Post Introduction Evaluation (PIE)</li> <li>b. Coverage survey</li> <li>c. Costing analysis</li> </ol> </li> <li>3. A report of the assessment of adolescent health interventions, with conclusions about what interventions would be feasible for integration in year 2.               <ol style="list-style-type: none"> <li>a. If an adolescent health intervention is identified for joint delivery with HPV vaccine, the report should describe the identified intervention, the modified plans for Year 2, and the steps required for implementation with the district(s) and staff involved.</li> <li>b. If NO adolescent health intervention is identified for joint delivery with HPV vaccine the report should mention the reason why not.</li> </ol> </li> <li>4. A summary of the activities completed and progress towards the development of a national cervical cancer prevention and control strategy.</li> </ol>	<p>As soon as they become available, and at the latest by end of year 1 (the first year starts when the first dose of vaccine is administered, and continues for 12 months)</p>
<ol style="list-style-type: none"> <li>5. A financial and activity report of expenditures by the end of year 1.</li> </ol>	<p>End of year 1 (the first year starts when the first dose of vaccine is administered, and continues for 12 months)</p>
<ol style="list-style-type: none"> <li>1. If an adolescent health intervention is identified for joint delivery with HPV vaccine OR if the country substantially changed their delivery strategy:               <ol style="list-style-type: none"> <li>a. A new survey to measure the coverage of HPV vaccination and the coverage of the jointly delivered health intervention(s) and</li> <li>b. An updated micro-costing analysis of programme delivery costs. (Annex B)</li> </ol> </li> <li>2. If NO adolescent health intervention is identified for joint delivery with HPV vaccine in Year 2: A summary report of year 2 delivery of HPV vaccinations</li> <li>3. A financial and activity report of expenditures in year 2.</li> <li>4. A copy of the developed or revised national cervical cancer prevention and control strategy.</li> </ol>	<p>End of Year 2 (the second year starts when the first dose of vaccine is administered to a new cohort, which is usually 12 months after the start of Year 1 and continues for twelve calendar months)</p>

**17. Financial Clarifications:** Not applicable

18. Other conditions: Not applicable

**On behalf of Gavi**

Signed by:



Hind Khatib-Othman  
Managing Director, Country Programmes  
2 July 2015